AU2018273382A1 - Novel use of a formyl peptide receptor 2/ lipoxin A4 receptor (FPR2/ALX) agonist for treatment of heart failure - Google Patents

Novel use of a formyl peptide receptor 2/ lipoxin A4 receptor (FPR2/ALX) agonist for treatment of heart failure Download PDF

Info

Publication number
AU2018273382A1
AU2018273382A1 AU2018273382A AU2018273382A AU2018273382A1 AU 2018273382 A1 AU2018273382 A1 AU 2018273382A1 AU 2018273382 A AU2018273382 A AU 2018273382A AU 2018273382 A AU2018273382 A AU 2018273382A AU 2018273382 A1 AU2018273382 A1 AU 2018273382A1
Authority
AU
Australia
Prior art keywords
compound
heart failure
treatment
heart
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2018273382A
Other languages
English (en)
Inventor
Nancy Leigh CARSON
Ricardo Garcia
Jacek Ostrowski
Nicholas R. Wurtz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62567841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2018273382(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AU2018273382A1 publication Critical patent/AU2018273382A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2018273382A 2017-05-22 2018-05-22 Novel use of a formyl peptide receptor 2/ lipoxin A4 receptor (FPR2/ALX) agonist for treatment of heart failure Abandoned AU2018273382A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762509489P 2017-05-22 2017-05-22
US62/509,489 2017-05-22
PCT/US2018/033783 WO2018217684A1 (en) 2017-05-22 2018-05-22 Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure

Publications (1)

Publication Number Publication Date
AU2018273382A1 true AU2018273382A1 (en) 2020-01-16

Family

ID=62567841

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018273382A Abandoned AU2018273382A1 (en) 2017-05-22 2018-05-22 Novel use of a formyl peptide receptor 2/ lipoxin A4 receptor (FPR2/ALX) agonist for treatment of heart failure

Country Status (15)

Country Link
US (1) US20200069644A1 (enExample)
EP (1) EP3630097A1 (enExample)
JP (1) JP2020520948A (enExample)
KR (1) KR20200006595A (enExample)
CN (1) CN110662538A (enExample)
AU (1) AU2018273382A1 (enExample)
BR (1) BR112019024185A2 (enExample)
CA (1) CA3064291A1 (enExample)
CL (1) CL2019003325A1 (enExample)
CO (1) CO2019013015A2 (enExample)
EA (1) EA201992704A1 (enExample)
IL (1) IL270749A (enExample)
MX (1) MX2019013926A (enExample)
PE (1) PE20200402A1 (enExample)
WO (1) WO2018217684A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2869129T3 (es) * 2017-06-09 2021-10-25 Bristol Myers Squibb Co Agonistas de piperidinona del receptor 2 de péptidos formilados
JP7700210B2 (ja) 2020-07-09 2025-06-30 ブリストル－マイヤーズ スクイブ カンパニー ピラゾロンホルミルペプチド２受容体アゴニスト
JP7802765B2 (ja) 2020-08-12 2026-01-20 ブリストル－マイヤーズ スクイブ カンパニー オキソピロリジン尿素ｆｐｒ２アゴニスト
KR20230084530A (ko) * 2020-10-09 2023-06-13 브리스톨-마이어스 스큅 컴퍼니 아미노이미다졸 fpr2 효능제
CN119055775A (zh) * 2022-07-30 2024-12-03 中国医学科学院阜外医院 Jun抑制剂在制备用于治疗射血分数保留的心衰的药物中的用途
CN118831080B (zh) * 2024-09-24 2024-11-22 上海交通大学医学院附属仁济医院 5-氧脯氨酸在制备预防或治疗心肌病的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1492552A2 (en) * 2002-04-03 2005-01-05 Bayer Aktiengesellschaft Diagnostics and therapeutics for diseases associated with n-formyl peptide receptor like 1 (fprl1)
NZ752095A (en) 2013-11-28 2022-07-01 Kyorin Seiyaku Kk Urea derivative or pharmacologically acceptable salt thereof
KR101645015B1 (ko) * 2014-03-11 2016-08-03 포항공과대학교 산학협력단 Fpr2를 활성화하는 물질을 포함하는, 인슐린 저항성 관련 질환 치료용 조성물

Also Published As

Publication number Publication date
WO2018217684A1 (en) 2018-11-29
US20200069644A1 (en) 2020-03-05
CL2019003325A1 (es) 2020-04-17
PE20200402A1 (es) 2020-02-26
CN110662538A (zh) 2020-01-07
IL270749A (en) 2020-01-30
CO2019013015A2 (es) 2020-01-17
CA3064291A1 (en) 2018-11-29
EP3630097A1 (en) 2020-04-08
EA201992704A1 (ru) 2020-03-19
BR112019024185A2 (pt) 2020-06-02
MX2019013926A (es) 2020-01-20
KR20200006595A (ko) 2020-01-20
JP2020520948A (ja) 2020-07-16

Similar Documents

Publication Publication Date Title
US20200069644A1 (en) Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure
TWI900606B (zh) 用於治療內皮素相關疾病之齊泊騰坦和達格列淨的組合
EP2846787A2 (en) New methods
EA012600B1 (ru) Применение антагониста рецептора ангиотензина ii телмисартана для повышения чувствительности к инсулину
JP2022523645A (ja) ミトコンドリアミオパチーの処置におけるＰＰＡＲδアゴニストの使用
US6740648B2 (en) Treatment of pulmonary hypertension
AU2022299103B2 (en) Methods of using aldosterone synthase inhibitors
Shi et al. The histone deacetylase inhibitor SAHA exerts a protective effect against myocardial ischemia/reperfusion injury by inhibiting sodium-calcium exchanger
US20240148735A1 (en) Methods of treating heart failure with vibegron
MX2010011873A (es) Uso de dronedarona para preparar un medicamento para el tratamiento de pacientes con arritmia y que tienen un incremento del nivel de creatinina debido a la administracion de dronedarona.
JP6688503B2 (ja) 医薬用組成物
SK19332001A3 (sk) Použitie antagonistov kortizolu v liečení srdcového zlyhania
JP2025513337A (ja) 心原性ショック前および心原性ショックの処置のためのイスタロキシムを含む静脈内注入製剤
US12419863B2 (en) Pharmaceutical composition for use in treatment of hypertrophic cardiomyopathy
TW201904584A (zh) 減少或預防第ｉｉ型糖尿病患者中心血管事件之方法
EP4376843A1 (en) Treatment of hfpef in post-menopausal women with an sgc stimulator
Giri et al. Cardioprotective role of peroxisome proliferator-activated receptor-γ agonist, rosiglitazone in a unique murine model of diabetic cardiopathy
US20070032557A1 (en) Method for administering levosimendan
WO2023200738A1 (en) Combination treatment of dilated cardiomyopathy comprising a tyrosine kinase inhibitor and a statin
US20230381190A1 (en) Methods and Treatment for Complex Lymphatic Malformations
Dulce et al. Synthetic Growth Hormone-Releasing Hormone Agonist as Novel Treatment for Heart Failure with Preserved Ejection Fraction
WO2025198687A1 (en) Methods for treating heart diseases
CN121793966A (zh) 治疗扩张型心肌病的方法
Mystakidou FACULTY OF HEALTH SCIENCES
Elijovich et al. Salt Sensitivity of Blood Pressure: A Contributor to Treatment-Refractory Resistant Hypertension

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period